Curio Biotech SA


Curio Biotech is a science-based private Contract Research Organization offering personalized research services in the pharma/nutrition and cosmetic sectors. It is located at BioArk, Biotechnology park in Visp, Switzerland. Taking advantage of decades of experience with primary human cell and molecular biology methods, it provides in vitro services at the discovery and preclinical stages of biopharma drug development as well as the required bio analytics. For all in vitro purposes, it has developed several cell culture media and cryopreservation formulations that can be used for cell line adaptation for efficient biologics production and for cellular therapies. Furthermore, Curio Biotech provides in vitro services related to safety testing (OECD tests) and in vitro toxicity.  
Curio Biotech has delivered services related to dermatology, immuno-oncology, stem cell biology and vascular biology. It invests in internal R&D to understand and develop novel bioassays using primary human cells to demonstrate the Mode of Action (MOA) and platform technologies for functional screening of drugs/compound libraries. For example, Curio Biotech recently developed a method for anti-IL-1 beta therapies and qualifying adult primary human endothelial cells for anti-vegf therapies as an alternative to fetal endothelial cells.